Lilly Financial Results: Q1 2019
Lilly has announced its financial results, including earnings, for the first quarter of 2019.
"Lilly continued to execute well against our strategic priorities in the first quarter of 2019," said Dave Ricks, Lilly's chairman and CEO. "We delivered volume-based revenue growth despite the loss of patent exclusivity for several products, increased our investments in new brands, and further funded our pipeline of potential new medicines. We also completed two transformative transactions in the first quarter, the disposition of our remaining ownership in Elanco Animal Health and the acquisition of Loxo Oncology, which adds a potential 2020 launch and strengthens our oncology pipeline of precision medicines for patients with difficult to treat cancers."
Read the press release
Listen to the investor webcast
Download the investor presentation
View Lilly's clinical development pipeline
Read Lilly executive committee biographies
- View Lilly's key facts
For more information, visit Lilly's Investor Relations website.